Dual TLR2 and TLR7 agonists as HIV latency-reversing agents

The presence of a reservoir of latently infected cells in HIV-infected patients is a major barrier towards finding a cure. One active cure strategy is to find latency-reversing agents that induce viral reactivation, thus leading to immune cell recognition and elimination of latently infected cells,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JCI Insight
Egile Nagusiak: Macedo, Amanda B., Novis, Camille L., De Assis, Caroline M., Sorensen, Eric S., Moszczynski, Paula, Huang, Szu-han, Ren, Yanqin, Spivak, Adam M., Jones, R. Brad, Planelles, Vicente, Bosque, Alberto
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Clinical Investigation 2018
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6237480/
https://ncbi.nlm.nih.gov/pubmed/30282829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.122673
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak